Details of the Drug

General Information of Drug (ID: DM89NIB)

Drug Name
UX143
Indication
Disease Entry ICD 11 Status REF
Osteogenesis imperfecta LD24.K0 Phase 3 [1]
Drug Type
Antibody
Cross-matching ID
TTD ID
DG8VN2

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Sclerostin (SOST) TTYRO4F SOST_HUMAN Not Available [2]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Osteogenesis imperfecta
ICD Disease Classification LD24.K0
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Sclerostin (SOST) DTT SOST 1.11E-01 0.9 2.87
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

References

1 ClinicalTrials.gov (NCT05768854) An Open-label, Randomized, Active-Controlled, Phase 3 Study of Setrusumab Compared With Bisphosphonates in Pediatric Subjects With Osteogenesis Imperfecta Types I, III or IV. U.S.National Institutes of Health.
2 Clinical pipeline report, company report or official report of Ultragenyx Pharmaceutical